Skip to footer
Navajo Tech U Education and Research for Animal Care and Human Health (20190909-OPPE-LSC-1009).jpg
Photo: USDAgov, Public domain, via Wikimedia Commons

business

Safi Biotherapeutics Secures $4.7 Million Defense Award for Red Blood Cells

Safi Biotherapeutics secures $4.7M U.S. defense award to develop manufactured red blood cells for 2027 clinical trial.

Updated 1 min read

Published by Agyata NewsroomEditorial policyCorrections

Key points

  • Safi Biotherapeutics secured a $4.7 million non-dilutive award extension from the U.S. Defense Health Program.
  • The funding supports development activities required before the company's first planned clinical trial.
  • The award brings cumulative non-dilutive government funding to more than $27 million.

Why it matters. This funding supports the critical work needed to file the company's IND and initiate its first clinical trial in 2027, aiming to address blood supply fragility in hospitals and military settings.

Updated Sources: Pulse 2.0

Safi Biotherapeutics received a $4.7 million non-dilutive award extension from the U.S. Defense Health Program to advance its manufactured red blood cell technology. This funding, channeled through the Medical Technology Enterprise Consortium, will enable the company to reach its goal of filing an Investigational New Drug submission in 2027.

Latest updates

Safi Biotherapeutics Secures $4.7 Million Defense Award for Red Blood Cells

Safi Biotherapeutics, a biotechnology firm developing manufactured human red blood cells, has been awarded a $4.7 million extension from the U.S. government's Defense Health Program. The funding, provided through the Medical Technology Enterprise Consortium under the Combat Casualty Care portfolio, will support further development of the technology. This innovation aims to provide reliable blood supplies for civilian and military transfusions without the need for traditional donor blood. The award is non-dilutive, meaning it does not require the company to issue new shares.

Pulse 2.0

Sources

AI-assisted summary of the reporting above. Quotes are kept to one sentence. Copyright concern? See our DMCA takedown page.